Hysteroid dysphoria: Difference between revisions
m →Treatment: typo fix |
|||
Line 33: | Line 33: | ||
== Treatment == |
== Treatment == |
||
While some research shows that hysteroid dysphoria responds well to [[Monoamine oxidase inhibitor|MAOIs]], other research has suggested that the difference actually comes from the condition being less sensitive to tricyclic antidepressants.<ref>{{Cite journal|url=https://europepmc.org/article/med/17201029|title=New Directions in the Treatment of Atypical Depression|journal=The Journal of Clinical Psychiatry|date=2006 |pmid=17201029 |access-date=2020-02-13 |last1=Thase |first1=M. E. |volume=67 |issue=12 |article-number=e18 |doi=10.4088/jcp.1206e18 }}</ref> Tricyclic antidepressants are regarded as unsuccessful treatment for hysteroid dysphoria particularly due to this medication being specialised for treating typical forms of depression, rather than atypical forms, such as |
While some research shows that hysteroid dysphoria responds well to [[Monoamine oxidase inhibitor|MAOIs]], other research has suggested that the difference actually comes from the condition being less sensitive to tricyclic antidepressants.<ref>{{Cite journal|url=https://europepmc.org/article/med/17201029|title=New Directions in the Treatment of Atypical Depression|journal=The Journal of Clinical Psychiatry|date=2006 |pmid=17201029 |access-date=2020-02-13 |last1=Thase |first1=M. E. |volume=67 |issue=12 |article-number=e18 |doi=10.4088/jcp.1206e18 }}</ref> Tricyclic antidepressants are regarded as unsuccessful treatment for hysteroid dysphoria particularly due to this medication being specialised for treating typical forms of depression, rather than atypical forms, such as hysteroid dysphoria.<ref name=":5">{{Cite journal |last=Sabella |first=Donna |date=2018 |title=MENTAL HEALTH MATTERS: Antidepressant Medications |url=https://www.jstor.org/stable/26620874 |journal=The American Journal of Nursing |volume=118 |issue=9 |pages=52–59 |doi=10.1097/01.NAJ.0000544978.56301.f6 |jstor=26620874 |pmid=30138204 |issn=0002-936X}}</ref> |
||
MAOIs have been identified as a successful biological treatment for hysteroid dysphoric individuals. This is due to MAOIs catering to forms of treatment-resistant depression. The side effects of MAOIs vary across users, and may include insomnia, weight gain, and sexual dysfunction.<ref name=":5" /> |
MAOIs have been identified as a successful biological treatment for hysteroid dysphoric individuals. This is due to MAOIs catering to forms of treatment-resistant depression. The side effects of MAOIs vary across users, and may include insomnia, weight gain, and sexual dysfunction.<ref name=":5" /> |
Revision as of 16:28, 17 July 2024
Hysteroid dysphoria is a name given to repeated episodes of depressed mood in response to feeling rejected.[1]
There is a common misconception surrounding whether hysteroid dysphoria and rejection sensitivity are the same disorder. Hysteroid dysphoria was previously defined in psychiatry as ‘Rejection Sensitive Hysteroid Dysphoria’. This definition was changed to hysteroid dysphoria. Thus, hysteroid dysphoria and rejection sensitivity are sometimes used interchangeably.[2]
Currently, hysteroid dysphoria is regarded as an outdated term amongst most psychiatric diagnostic manuals, such as the DSM-5.[3] Thus, this disorder is not formally classified as a social personality disorder. However, the symptoms of hysteroid dysphoria remain prevalent across a variety of social personality and mood disorders.[4]
Symptoms
Hysteroid dysphoria has been described in outpatient populations and is thought to be a subtype of atypical depression involving rejection sensitivity and therapeutic response to monoamine oxidase inhibitors.[5]
The most prominent symptoms associated with hysteroid dysphoria include low-self esteem and intense feelings of rejection.[2] In response to this, individuals may feel a tendency to withdraw from social situations.
As a result, individuals with hysteroid dysphoria are susceptible to experiencing social isolation, loneliness, and difficulties with forming and sustaining romantic relationships.[2]
Notably, symptoms of hysteroid dysphoria may vary in how they are displayed. The symptoms can be categorised as either ‘internal’ or ‘external’. The internal symptoms refer to the cognitive and emotional experiences that may not be observable to others. The external symptoms of hysteroid dysphoria effect social interactions. They can be displayed as a physiological expression of the internal mental processes that are a consequence of the disorder.[4]
Studies
The term ‘hysteroid dysphoria’ was first introduced into the field of psychiatry by Klein and Liebowitz in 1979. Their pioneering work derived from research conducted on a subgroup of depressed patients, reporting a consistent pattern of "repeated depressed moods in response to feeling rejected" among the participants.[6]
Other studies have examined the symptoms associated with hysteroid dysphoria and found that while the symptoms are observable, they are not unique or distinct enough to be considered their own condition.[7] In 2006, Spitzer and Williams conducted research to identify the syndromal validity of hysteroid dysphoria. In a sample of 1,324 patients identified with symptoms of mild depression, 3.1% displayed atypical features. These patients were not more likely to display more atypical features than others. Thus, Spitzer and Williams concluded that hysteroid dysphoria does not meet criteria to be acknowledged as a distinct syndrome.[7]
Contributing factors
Biological factors
The biological explanations of the causes of hysteroid dysphoria remain limited. However, it has been suggested that the dysregulation of the production of the oxytocin receptor gene (OXTR) is associated with the onset of hysteroid dysphoric symptoms.[8] This has been suggested due to the oxytocin hormone being associated with regulating behaviours related to social affiliation and emotional regulation.[8] Thus, the dysfunction of this hormone can lead to difficulties with social bonding and social cognition, specifically the ability to interpret social cues.
Additional research indicates that cortical association influences the development of symptoms associated with hysteroid dysphoria. Feelings of social rejection activate cortical regions that are also linked to physical pain, including the anterior insula and the dorsal anterior cingulate cortex.[9]
Environmental factors
Wider societal changes have been identified as influencing factors in the onset of hysteroid dysphoria. For instance, recent research has discovered that the COVID-19 pandemic has enhanced psychiatric symptoms. Individuals reported a lack of social connectedness as a response to the periods of social isolation. This reinforced the symptoms of hysteroid dysphoria, specifically intense feelings of social rejection.[10]
Social interactions with others also contribute to the development of symptoms associated with hysteroid dysphoria . The role of peer victimisation has been discovered as a possible influence in heightened rejection sensitivity amongst individuals.[11] A study of 1039 adolescents analysed the multiple dimensions of peer victimisation: experience of bullying, physical and social aggression, and sexual harassment. The correlational findings displayed that peer victimisation is strongly associated with higher levels of rejection sensitivity amongst participants.[11]
Treatment
While some research shows that hysteroid dysphoria responds well to MAOIs, other research has suggested that the difference actually comes from the condition being less sensitive to tricyclic antidepressants.[12] Tricyclic antidepressants are regarded as unsuccessful treatment for hysteroid dysphoria particularly due to this medication being specialised for treating typical forms of depression, rather than atypical forms, such as hysteroid dysphoria.[13]
MAOIs have been identified as a successful biological treatment for hysteroid dysphoric individuals. This is due to MAOIs catering to forms of treatment-resistant depression. The side effects of MAOIs vary across users, and may include insomnia, weight gain, and sexual dysfunction.[13]
If the use of MAOIs have proven to be ineffective in reducing the symptoms of hysteroid dysphoria, other forms of treatment include psychotherapy.[14] This enables individuals with such symptoms learn how to effectively process their emotions and exert greater control of their emotional responses.
Criticisms
Co-morbidity
The inability for hysteroid dysphoria to be classified as its own unique condition is attributed to its co-morbidity with other disorders. The symptoms of hysteroid dysphoria share similarities with a variety of mood disorders.[4] Some of which include:
- Histrionic personality disorder, characterized by an overwhelming desire to be noticed by others.
- Bipolar disorder due to the instability of emotions.
- Social anxiety disorder due to the withdrawal from social situations in response to feeling rejected.
ADHD has been identified as highly co-morbid with hysteroid dysphoria.[15] One notable similarity lies in the comparable structure of the neuroendocrine system. Neuroimaging research has revealed that ADHD targets hypothalamic pituitary adrenal (HPA), a region of the brain that governs and regulates bodily stress. This has shown to induce symptoms of hysteroid dysphoria among individuals.[16] Further analysis of brain scans suggests that both disorders result from interference in the brain’s communication systems, specifically systems that govern emotion and attention.[17]
Methodological issues
Much of the understanding of hysteroid dysphoria is based on research with predominantly female participants. Consequently, this has led to a common misconception that hysteroid dysphoria is most prevalent amongst women. However, some research has suggested that the symptoms of hysteroid dysphoria manifest differently across men and women.[18] The degree of rejection sensitivity in participants was measured using a ‘rejection sensitive questionnaire’ and attitudes towards intimacy were identified using a ‘fear of intimacy scale’. Analysis of the gender differences in intimate relationships has shown that females with higher rejection sensitivity display greater fear of intimate relationships compared to their male counterparts.Some differences included females displaying greater hostility in relationships whereas men may display subtle signs of jealousy.[18]
Some research has suggested that the symptoms of hysteroid dysphoria may be sufficient to define this as a distinct disorder. Research has discovered some differences between ADHD and hysteroid dysphoria, particularly in terms of the duration of the disorders. ADHD has been identified as a life-long disorder whereas symptoms associated with hysteroid dysphoria are regarded as “brief” and tend to “dissipate rapidly.” [19] This observation has promted a focus on the potential for hysteroid dysphoria to be distinct from ADHD, with some suggestion that this disorder may instead be a sub-symptom of ADHD.[4]
See also
References
- ^ Møller, SE (1992). "Serotonin, carbohydrates, and atypical depression". Pharmacology & Toxicology. 71 (Suppl 1): 61–71. doi:10.1111/j.1600-0773.1992.tb01630.x. PMID 1480561.
- ^ a b c Liebowitz, Michael R.; Klein, Donald F. (1979-12-01). "Hysteroid Dysphoria". Psychiatric Clinics of North America. Affective Disorders: Special Clinical Forms. 2 (3): 555–575. doi:10.1016/S0193-953X(18)30996-1. ISSN 0193-953X.
- ^ Diagnostic and Statistical Manual of Mental Disorders. American Psychiatric Association. 2022. doi:10.1176/appi.books.9780890425787. ISBN 978-0-89042-575-6 – via DSM Library.
- ^ a b c d "New Insights Into Rejection Sensitive Dysphoria". ADDitude. 2020-07-29. Retrieved 2024-03-19.
- ^ Beeber, AR; Kline, MD; Pies, RW; Manring, JM Jr (1984). "Hysteroid dysphoria in depressed inpatients". Journal of Clinical Psychiatry. 45 (4): 164–166. PMID 6715288.
- ^ Liebowitz, Michael R.; Klein, Donald F. (1979). "Hysteroid Dysphoria". Psychiatric Clinics of North America. 2 (3): 555–575. doi:10.1016/S0193-953X(18)30996-1.
- ^ a b Spitzer, R. L. (2006). "Hysteroid dysphoria: an unsuccessful attempt to demonstrate its syndromal validity". American Journal of Psychiatry. 139 (10): 1286–1291. doi:10.1176/ajp.139.10.1286. ISSN 0002-953X. PMID 7124981.
- ^ a b Woods, Robbie; Bedard, Marc; McQuaid, Robyn Jane; Matheson, Kim; Anisman, Hymie (2018-05-04). "Rejection sensitivity and multiple group memberships: The moderating role of an oxytocin receptor gene polymorphism". Social Neuroscience. 13 (3): 268–276. doi:10.1080/17470919.2017.1327458. ISSN 1747-0919. PMID 28472899.
- ^ Kross, Ethan; Berman, Marc G.; Mischel, Walter; Smith, Edward E.; Wager, Tor D. (2011-04-12). "Social rejection shares somatosensory representations with physical pain". Proceedings of the National Academy of Sciences. 108 (15): 6270–6275. Bibcode:2011PNAS..108.6270K. doi:10.1073/pnas.1102693108. ISSN 0027-8424. PMC 3076808. PMID 21444827.
- ^ Hsu, David T.; Jarcho, Johanna M. (2021-01-01). ""Next up for psychiatry: rejection sensitivity and the social brain"". Neuropsychopharmacology. 46 (1): 239–240. doi:10.1038/s41386-020-00802-9. ISSN 1740-634X. PMC 7424132. PMID 32792681.
- ^ a b Nepon, Taryn; Pepler, Debra J.; Craig, Wendy M.; Connolly, Jennifer; Flett, Gordon L. (2021). "A Longitudinal Analysis of Peer Victimization, Self-Esteem, and Rejection Sensitivity in Mental Health and Substance Use Among Adolescents". International Journal of Mental Health and Addiction. 19 (4): 1135–1148. doi:10.1007/s11469-019-00215-w. ISSN 1557-1874.
- ^ Thase, M. E. (2006). "New Directions in the Treatment of Atypical Depression". The Journal of Clinical Psychiatry. 67 (12) e18. doi:10.4088/jcp.1206e18. PMID 17201029. Retrieved 2020-02-13.
- ^ a b Sabella, Donna (2018). "MENTAL HEALTH MATTERS: Antidepressant Medications". The American Journal of Nursing. 118 (9): 52–59. doi:10.1097/01.NAJ.0000544978.56301.f6. ISSN 0002-936X. JSTOR 26620874. PMID 30138204.
- ^ Bronswijk, Suzanne van; Moopen, Neha; Beijers, Lian; Ruhe, Henricus G.; Peeters, Frenk (2019). "Effectiveness of psychotherapy for treatment-resistant depression: a meta-analysis and meta-regression". Psychological Medicine. 49 (3): 366–379. doi:10.1017/S003329171800199X. ISSN 0033-2917. PMID 30139408.
- ^ Beaton, Danielle M.; Sirois, Fuschia; Milne, Elizabeth (2022-02-18). "Experiences of criticism in adults with ADHD: A qualitative study". PLOS ONE. 17 (2): e0263366. Bibcode:2022PLoSO..1763366B. doi:10.1371/journal.pone.0263366. ISSN 1932-6203. PMC 8856522. PMID 35180241.
- ^ Chang, Jane Pei-Chen; Su, Kuan-Pin; Mondelli, Valeria; Pariante, Carmine M. (2021-08-19). "Cortisol and inflammatory biomarker levels in youths with attention deficit hyperactivity disorder (ADHD): evidence from a systematic review with meta-analysis". Translational Psychiatry. 11 (1): 430. doi:10.1038/s41398-021-01550-0. ISSN 2158-3188. PMC 8377148. PMID 34413283.
- ^ Shaw, Philip; Stringaris, Argyris; Nigg, Joel; Leibenluft, Ellen (2014). "Emotion Dysregulation in Attention Deficit Hyperactivity Disorder". American Journal of Psychiatry. 171 (3): 276–293. doi:10.1176/appi.ajp.2013.13070966. ISSN 0002-953X. PMC 4282137. PMID 24480998.
- ^ a b Giovazolias, Theodoros; Paschalidi, Eirini (2022-05-05). "The Effect of Rejection Sensitivity on Fear of Intimacy in Emerging Adulthood". European Journal of Psychology Open. 81 (1): 1–12. doi:10.1024/2673-8627/a000019. ISSN 2673-8627.
- ^ Bedrossian, Louise (2021). "Understand and address complexities of rejection sensitive dysphoria in students with ADHD". Disability Compliance for Higher Education. 26 (10): 4. doi:10.1002/dhe.31047. ISSN 1086-1335.